

GENOMIC VALLEY BIOTECH LTD.

Regd. Off: 4 KM STONE BERI CHHARA ROAD, TEHSIL-BAHADURGARH
DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1996PLC033029
Tele :- +91-9811341542
Email : genomicvalley@gmail.com
Visit : <http://www.genomicvalley.com>

Dated: 11th February, 2017

To,
BSE Limited
PhirozeJeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400001
Email ID: corp.relations@bseindia.com

Ref: Genomic Valley Biotech Limited (539206/ GVBL)

Sub: Outcome of the Board Meeting held on 11th February, 2017

Dear Sir/Madam,

Pursuant to the Regulation 30 and any other applicable regulations of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors at its meeting held on 11th February, 2017, has inter-alia, approved the Un-audited Financial Results of the Company for the Quarter and Nine Months ended 31st December, 2016.

Further pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Un-audited Financial Results of the Company for the Quarter and Nine Months ended 31st December, 2016.

We are also enclosing a copy of the Limited Review Report of the Auditors of the Company, as required under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The aforesaid Board Meeting commenced at 11:45 AM and concluded at 01:30 P.M.

This is for your information and records.

Please acknowledge the receipt.

Thanking you.

Yours faithfully,

**For and on behalf of
Genomic Valley Biotech Limited**

Hitesh

**Hitesh Kumar
Company Secretary & Compliance officer**



Encl: A/A

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 KM STONE BERI CHHARA ROAD, TEHSIL-BAHADURGARH
DISTT-JHAJJAR, HARYANA
CIN: L01122HR1996PLC033029

Genomic Valley Biotech Limited today reported its financial performance for the Quarter and Nine Months ended
31 December 2016

Highlights of the Un-Audited Financial Results as compared to the previous year are:

PART I (Amount in ₹)

Sr. No.	Particular	Quarter Ended			Nine Month Ended		Year Ended
		31-Dec-16 Unaudited	30-Sep-16 Unaudited	31-Dec-15 Unaudited	31-Dec-16 Unaudited	31-Dec-15 Unaudited	31-Mar-16 Audited
	Part I						
1	Income From Operations						
	a) Net Sales/Income From Operations (Net of excise duty)	786,000.00	960,450.00	268,000.00	3,196,344.00	824,540.00	1,090,205.00
	b) Other Operating Income	-	-	-	-	-	-
	Tota income from operation (net)	786,000.00	960,450.00	268,000.00	3,196,344.00	824,540.00	1,090,205.00
2	Expenses	-	-	-	-	-	-
(a)	Cost of materials consumed	266,381.00	440,075.00	183,795.00	948,972.00	662,985.00	729,289.00
(b)	Purchases of Stock-in-Trade	-	-	-	-	-	-
(c)	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-	-	-
(d)	Employee benefits expense	685,801.00	730,521.00	318,112.00	1,670,419.00	1,104,612.00	1,337,816.00
(e)	Depreciation and amortization expense	122,317.86	122,317.86	124,213.67	363,747.32	372,641.01	501,954.68
(f)	Other expenses (Any item exceeding 10% of the total expenses relating to continuing operation to be shown seprately)	235,665.90	391,824.68	1,438,065.00	1,014,555.78	3,312,937.72	3,619,174.72
	Total Expenses	1,310,165.76	1,684,738.54	2,064,185.67	3,997,694.10	5,453,175.73	6,188,234.40
3	Profit / (Loss) from operations before other income, finance costs and exceptional item	-524,165.76	-724,288.54	-1,796,185.67	-801,350.10	-4,628,635.73	-5,098,029.40
4	Other Income	154,750.00	104,750.00	1,827,063.18	-123,421.83	2,890,284.06	1,649,603.73
5	Profit/loss from ordinary activity before financial cost & exceptional items(3±4)	-369,415.76	-619,538.54	30,877.51	-924,771.93	-1,738,351.67	-3,448,425.67
6	Financial cost	-	-	-	-	-	-
7	Profit from ordinary activity after financial cost but before exception item	-369,415.76	-619,538.54	30,877.51	-924,771.93	-1,738,351.67	-3,448,425.67
8	Exceptional Item	-	-	-	-	-	-
9	Profit From ordinary activities before tax	-369,415.76	-619,538.54	30,877.51	-924,771.93	-1,738,351.67	-3,448,425.67
10	Tax expenses	-	-	-	-	-	-100,600.00
11	Net Profit/(Loss) from ordinary activities after tax	-369,415.76	-619,538.54	30,877.51	-924,771.93	-1,738,351.67	-3,347,825.67
12	Extraordinary item	-	-	-	-	-	-

Paul Agrawal


13	Net profit/(Loss) for the period	-369,415.76	-619,538.54	30,877.51	-924,771.93	-1,738,351.67	-3,347,825.67
14	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	3,054,500.00	3,054,500.00	3,054,500.00	3,054,500.00	3,054,500.00	3,054,500.00
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	15,085,115.86	15,085,115.86	18,432,941.53	15,085,115.86	18,432,941.53	15,085,115.86
	Earning Per Share	-	-	-	-	-	-
	(a) Basic	-0.12	-0.20	0.01	-0.30	-0.57	-1.10
	(b) Diluted	-0.12	-0.20	0.01	-0.30	-0.57	-1.10

PART II

Sr. No.	Particular	Quarter Ended			Nine Month Ended		Year Ended
		31-Dec-16	30-Sep-16	31-Dec-15	31-Dec-16	31-Dec-15	31-Mar-16
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A	<u>PARTICULAR OF SHAREHOLDING</u>						
1	Public Shareholdin						
	Number of Shares	1,092,800.00	1,092,800.00	1,092,800.00	1,092,800.00	1,092,800.00	1,092,800.00
	Percentage of Shareholding	35.78%	35.78%	35.78%	35.78%	35.78%	35.78%
2	Promoters and Promoters Group Shareholding						
	a) Pledge/Encumbered						
	Number of Shares	0	0	0	0	0	0
	Percentage of Shares (as a % of the total Shareholding of Promoter and Promoter Group)	0	0	0	0	0	0
	Percentage of Shares (as a % of the total share capital of the Company)	0	0	0	0	0	0
	b) Non - encumbered						
	Number of Shares	1,961,700.00	1,961,700.00	1,961,700.00	1,961,700.00	1,961,700.00	1,961,700.00
	Percentage of Shares (as a % of the total Shareholding of the promoter and promoter Group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	Percentage of Shares (as a % of the total Share Capital of the Company)	64.22%	64.22%	64.22%	64.22%	64.22%	64.22%

B	<u>INVESTOR COMPLAINT</u>	
	<u>PARTICULAR</u>	3 Month ended 31-Dec-16
	Pending at the beginning of the quarter	0
	Received during the quarter	0
	Disposed of during the quarter	0
	Remaining unresolved at the end of the quarter	0


Paul Agrawal



Notes :

- 1 The above financial results were reviewed by the Audit Committee and were thereafter approved by Board of Directors of the Company at their respective meeting held on 11th February, 2017.
- 2 Tax expenses includes provision for current tax and deffered tax.
- 3 Previous period's Figures have been re-grouped and / re-arranged wherever considered necessary as per the revised format of the SEBI and amended Schedule III to the Companies Act, 2013 and to make their classification comparable with the current period.

For and on behalf of the Board of Genomic Valley Biotech Limited


Pankaj Agrawal
(Director)
DIN-01165188

Place : Delhi

Dated : 11.02.2017

Add: G-74, Pushkar Enclave,
Paschim Vihar, New Delhi-110063



A.K. Khattar & Associates
Chartered Accountants

112-A, Ground Floor, DDA Complex,
Jhandewalan Extn-1, New Delhi-110055
Ph: 011-23676383, 011-43570260

LIMITED REVIEW REPORT

Review Report to the Board of Directors of
Genomic Valley Biotech Limited

We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **Genomic Valley Biotech Limited** ('the Company') for the quarter ended **December 31, 2016**. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2400, *Engagement to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of

A.K. KHATTAR & ASSOCIATES

Chartered Accountants


(A.K. KHATTAR)

(Prop.)

(Membership No.-084960)

Place: Delhi

Date: 11/02/2017